BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III and Vulnerable Inflammation Parameter Registry
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2018
Price : $35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms BIOFLOW-III
- Sponsors BIOTRONIK
- 19 Jul 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 29 Nov 2015 Planned End Date changed from 1 Dec 2018 to 1 May 2021.
- 29 Nov 2015 Planned primary completion date changed from 1 Dec 2016 to 1 Apr 2018.